TINEA
MCID: DRM011
MIFTS: 52

Dermatophytosis (TINEA)

Categories: Infectious diseases, Skin diseases

Aliases & Classifications for Dermatophytosis

MalaCards integrated aliases for Dermatophytosis:

Name: Dermatophytosis 12 74 15 71 32
Tinea 71

Classifications:



External Ids:

Disease Ontology 12 DOID:8913
ICD9CM 34 110 110.9
NCIt 49 C26745
SNOMED-CT 67 47382004
ICD10 32 B35 B35.9
UMLS 71 C0011636 C0040247

Summaries for Dermatophytosis

Disease Ontology : 12 A cutaneous mycosis that results in fungal infection located in scalp, located in glabrous skin, or located in nail, has material basis in Ascomycota fungi that belong to a group called dermatophytes, which have the ability to utilize keratin as a nutrient source.

MalaCards based summary : Dermatophytosis, also known as tinea, is related to tinea manuum and tinea unguium, and has symptoms including fever, pruritus and exanthema. An important gene associated with Dermatophytosis is CARD9 (Caspase Recruitment Domain Family Member 9), and among its related pathways/superpathways are Innate Immune System and Defensins. The drugs Ketoconazole and Luliconazole have been mentioned in the context of this disorder. Affiliated tissues include scalp, glabrous skin and nail, and related phenotypes are hematopoietic system and homeostasis/metabolism

Wikipedia : 74 Dermatophytosis, also known as ringworm, is a fungal infection of the skin. Typically it results in a... more...

Related Diseases for Dermatophytosis

Diseases related to Dermatophytosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 264)
# Related Disease Score Top Affiliating Genes
1 tinea manuum 33.8 CBSL B4GALNT2
2 tinea unguium 33.4 SQLE CBSL CARD9 B4GALNT2
3 tinea profunda 33.1 CLEC7A CLEC6A CLEC4E CARD9
4 tinea corporis 32.9 SQLE DEFB4A CLEC6A CLEC4E CBSL CARD9
5 dermatomycosis 32.8 CBSL B4GALNT2
6 tinea cruris 32.6 SQLE FLNA DEFB4A CLEC6A CBSL CARD9
7 superficial mycosis 32.4 CLEC7A CLEC6A CBSL B4GALNT2
8 tinea pedis 32.1 TRIM4 SQLE HECTD4 CLEC7A CLEC6A CLEC4E
9 tinea capitis 32.0 SQLE SLC7A1 FLNC ELOA3B CBSL CARD9
10 folliculitis 30.9 DEFB4A CD4 CCR6
11 fungal keratitis 30.7 CLEC7A CLEC4E
12 pustulosis of palm and sole 30.6 IL17A CCR6
13 candidiasis 30.5 LTF IL17A DEFB4A CLEC7A CARD9
14 cellulitis 30.5 DEFB4A CD4 CCR6
15 erythrasma 30.5 HECTD4 DEFB4A
16 aspergillosis 30.4 CSF1 CLEC7A CCR6
17 keratitis, hereditary 30.4 IL17A CD4 CCR6
18 pityriasis versicolor 30.3 SQLE CLEC7A CLEC6A CLEC4E CBSL
19 keratoconjunctivitis sicca 30.3 LTF CD4 CCR6
20 langerhans cell histiocytosis 30.1 IL17A CSF1 CCR6
21 t cell deficiency 30.0 IL17A CD4 CCR6
22 cutaneous candidiasis 29.9 IL17A CLEC7A CCR6 CARD9 B4GALNT2
23 bacterial infectious disease 29.8 LTF IL17A DEFB4A CD4 CCR6
24 pneumocystosis 29.7 FLNC CLEC7A CLEC6A CD4 CCR6
25 dermatitis, atopic 29.7 IL17A FLNC DEFB4A CD4 CCR6
26 leprosy 3 29.4 IL17A HECTD4 FLNA CD4 CCR6
27 chronic mucocutaneous candidiasis 29.3 IL17A CSF1 CLEC7A CLEC6A CLEC4E CD4
28 oral candidiasis 29.1 LTF IL17A DEFB4A CLEC7A CLEC6A CD4
29 nail disease 29.0 IL17A CLEC7A CLEC6A CLEC4E CD4 CCR6
30 chromoblastomycosis 28.8 CLEC7A CLEC6A CLEC4E CLEC4D CCR6 CBSL
31 deep dermatophytosis 12.7
32 tinea barbae 12.0
33 candidiasis, familial, 2 11.6
34 tinea imbricata 10.9
35 tinea favosa 10.7
36 alopecia 10.6
37 neuroaspergillosis 10.5 CLEC7A CARD9
38 haemophilus influenzae 10.5 LTF CLEC7A
39 skin disease 10.5
40 inflammatory bowel disease 1 10.4 DEFB4A CCR6 CARD9
41 proctitis 10.4 LTF CSF1 CCR6
42 suppurative lymphadenitis 10.4 CD4 CCR6
43 white piedra 10.4 CBSL B4GALNT2
44 keratosis 10.4
45 spongiotic dermatitis 10.4 CD4 CCR6
46 marginal corneal ulcer 10.4 FLNA DEFB4A
47 penicilliosis 10.4 CLEC7A CD4 CARD9
48 vaginitis 10.3 DEFB4A CD4 CCR6
49 anti-basement membrane glomerulonephritis 10.3 CD4 CCR6
50 allergic hypersensitivity disease 10.3

Comorbidity relations with Dermatophytosis via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hypertension, Essential

Graphical network of the top 20 diseases related to Dermatophytosis:



Diseases related to Dermatophytosis

Symptoms & Phenotypes for Dermatophytosis

UMLS symptoms related to Dermatophytosis:


fever, pruritus, exanthema

MGI Mouse Phenotypes related to Dermatophytosis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.1 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4D
2 homeostasis/metabolism MP:0005376 9.97 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4D
3 immune system MP:0005387 9.8 B4GALNT2 CARD9 CBSL CCR6 CD4 CLEC4D
4 respiratory system MP:0005388 9.23 CBSL CLEC4D CLEC7A CSF1 FLNA FLNC

Drugs & Therapeutics for Dermatophytosis

Drugs for Dermatophytosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 96)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketoconazole Approved, Investigational Phase 4 65277-42-1 47576
2
Luliconazole Approved Phase 4 187164-19-8
3
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
4
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
5
Efinaconazole Approved Phase 4 164650-44-6
6
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
7
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
8
Ciclopirox Approved, Investigational Phase 4 29342-05-0 2749
9 Gastrointestinal Agents Phase 4
10 Cytochrome P-450 CYP3A Inhibitors Phase 4
11 Cytochrome P-450 Enzyme Inhibitors Phase 4
12 Hormone Antagonists Phase 4
13 Steroid Synthesis Inhibitors Phase 4
14 Hormones Phase 4
15 Dermatologic Agents Phase 4
16 Antioxidants Phase 4
17 Protective Agents Phase 4
18 Pharmaceutical Solutions Phase 4
19 Anti-Ulcer Agents Phase 4
20 Proton Pump Inhibitors Phase 4
21 Antacids Phase 4
22 Micronutrients Phase 4
23 Trace Elements Phase 4
24 Selenium disulfide Phase 4
25 Nutrients Phase 4
26
Hydroxyitraconazole Phase 4
27 Antifungal Agents Phase 4
28 Anti-Infective Agents Phase 4
29
Sertaconazole Approved, Investigational Phase 3 99592-32-2 65863
30
Tolnaftate Approved, Investigational, Vet_approved Phase 3 2398-96-1 5510
31
Griseofulvin Approved, Investigational, Vet_approved Phase 3 126-07-8 441140
32
Econazole Approved Phase 3 27220-47-9 3198
33
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
34
Naftifine Approved Phase 3 65472-88-0 73342 47641
35
Amorolfine Approved, Investigational Phase 3 78613-35-1
36
Tavaborole Approved, Investigational Phase 3 174671-46-6
37
Albendazole Approved, Vet_approved Phase 2, Phase 3 54965-21-8 2082
38 Papaya Approved Phase 2, Phase 3
39
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
40
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
41
Betamethasone Approved, Vet_approved Phase 3 378-44-9 9782
42 Antiparasitic Agents Phase 2, Phase 3
43 Antimitotic Agents Phase 2, Phase 3
44 Antiprotozoal Agents Phase 2, Phase 3
45 Anthelmintics Phase 2, Phase 3
46 Antiemetics Phase 3
47 HIV Protease Inhibitors Phase 3
48 Anti-Asthmatic Agents Phase 3
49
protease inhibitors Phase 3
50 Anti-Inflammatory Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 An Open-Label Study to Assess the Pharmacokinetics With Maximal Use of Luliconazole Cream 1% in Pediatric Patients With Moderate to Severe Tinea Pedis or Tinea Cruris Completed NCT02767271 Phase 4 Luliconazole Cream 1%
2 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of NAFT-500 in Pediatric Subjects With Tinea Cruris and Tinea Pedis and NAFT-600 in Pediatric Subjects With Tinea Pedis Completed NCT01712360 Phase 4 NAFT500 (pediatric);NAFT600 (pediatric);NAFT500 (adult);NAFT600 (adult)
3 An Open-Label, Maximal Use Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Subjects With Tinea Pedis and Tinea Cruris Completed NCT02394340 Phase 4 Omeprazole 40 mg;Luliconazole Cream 1%
4 An Open-Label, Multi-Center, Multiple-Application Pharmacokinetic Study of Naftin® (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02466867 Phase 4 Naftin® Cream, 2% (younger pediatric cohort);Naftin® Cream, 2% (older pediatric cohort)
5 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Product 33525 in Pediatric Subjects With Tinea Corporis Completed NCT02767947 Phase 4 Luliconazole Cream 1%;Vehicle Cream
6 A Phase 4, Double-Blind, Randomized, Vehicle-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin (Naftifine Hydrochloride) Cream, 2% in Pediatric Subjects With Tinea Corporis Completed NCT02227290 Phase 4 Naftin Cream;Placebo Cream
7 Ketoconazole Foam 2% for the Treatment of Versicolor Completed NCT00830388 Phase 4 Ketoconazole 2% Foam
8 A Pilot Study - Safety and Efficacy of Nailprotex® for Onychomycosis Treatment Completed NCT02464826 Phase 4 Nailprotex
9 An Open-Label, Proof of Concept Study to Determine the Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis Completed NCT00824863 Phase 4 ketoconazole 2% foam
10 An Investigator Initiated Pilot Study Evaluating the Efficacy of Efinaconazole 10% Solution (Jublia) for the Treatment of Onychomycosis With Dermatophytomas Completed NCT03098615 Phase 4 Jublia (Efinaconazole 10% Topical Solution)
11 The Comparative Assessment of Mycological Efficacy, Safety, Recurrence, and Cost-effectiveness of Selenium Sulfide 1.8% Shampoo Versus Ketoconazole 2% Shampoo in Pityriasis Versicolor: a Double-blind Randomized Controlled Trial Completed NCT04007237 Phase 4 shampoo with different composition
12 Itraconazole in the Management of Superficial Fungal Infections in India. A Pilot Study Recruiting NCT03923010 Phase 4 Itraconazole
13 Study for the Assessment of Safety and Efficacy of Ciclopirox Olamine Cream in 3 Months to 10 Years Old Children With Dermatomycoses Terminated NCT01646580 Phase 4 ciclopirox
14 Efficacy Of Sertaconazole 2% (ERTACZO) in the Treatment of Interdigital Tinea Pedis With Once a Day Treatment for 4 Weeks Unknown status NCT00856596 Phase 3 Sertaconazole nitrate cream 2%
15 Study Clinical, Multicenter, Phase III, to Evaluate the Efficacy and Safety of Tolnaftate Cream in the Treatment of Patients With Fungal Infections Like Tinea Foot, Tinea and Tinea Crural Body" Unknown status NCT01105013 Phase 3 Clotrimazole
16 An Open-Label Study to Evaluate the Safety of Long-Term Administration of Product 33525 in Subjects With Tinea Pedis, Tinea Corporis, or Tinea Cruris Completed NCT01349998 Phase 3 Product 33525
17 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Cruris Completed NCT01342315 Phase 3 33525;Placebo
18 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396811 Phase 3 33525;Placebo
19 A Randomized, Multi-Center, Double-Blind, Vehicle-Controlled Study Evaluating the Efficacy and Safety of Product 33525 in Subjects With Tinea Pedis Completed NCT01396785 Phase 3 33525;Placebo
20 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
21 Clinical Study to Evaluate the Therapeutic Equivalence and Safety of Econazole Nitrate Cream, 1% (Renaissance Pharma, Inc.) to Econazole Nitrate Cream, 1% (Perrigo New York Inc.) in Tinea Pedis Completed NCT03129321 Phase 3 Econazole Nitrate Cream, 1%;Placebo
22 An Open Label, Multicenter Trial Of Diflucan (Fluconazole) For 6 Weeks Given Once Daily To Pediatric Patients With Tinea Capitis Completed NCT00645242 Phase 3 fluconazole
23 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group Study of the Efficacy and Safety of Terbinafine Film Forming Solution, 1% (as Hydrochloride), in Patients With Tinea Pedis Completed NCT01433107 Phase 3 Terbinafine;Terbinafine Placebo
24 A Double-blind, Randomized, Parallel-group, Vehicle-controlled, Multi-center Study to Evaluate the Safety and Clinical Equivalence of a Generic Ciclopirox Olamine Cream to Ciclopirox Cream 0.77% in the Treatment of Tinea Pedis Completed NCT00802672 Phase 3 Ciclopirox Olamine Cream;Loprox Cream 0.77%;Placebo
25 Efficacy and Safety of Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
26 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01289015 Phase 3 NAFT-600 ( naftin 2 % gel );Placebo
27 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Pedis Completed NCT00750139 Phase 3 NAFT-500;Placebo 2-weeks;Naftin 1%;Placebo 4-weeks
28 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-500 in Subjects With Tinea Cruris Completed NCT00750152 Phase 3 NAFT-500;Placebo
29 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison Study of the Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Interdigital Tinea Pedis Completed NCT01353976 Phase 3 Econazole Nitrate Foam 1%
30 A Randomized, Prospective Multicenter, Double Blind, Parallel Assignment Placebo Controlled BE Study Of Naftifine Hydrochloride 2% Topical Cream With Naftin® In Patients With Tinea Pedis Using Clinical Endpoints Completed NCT02633813 Phase 3 Naftifine hydrochloride 2%;Placebo;Naftin® 2% (Naftifine hydrochloride 2%)
31 A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multicenter, Parallel Group Evaluation of the Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris Completed NCT01885156 Phase 3 Naftin 1% Cream;Placebo Cream
32 A Randomized, Double-Blind, Vehicle-Controlled, Parallel-Design, Multiple-Site Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Encube Ethicals Pvt Ltd) to Ketoconazole Cream 2% (G&W Laboratories Inc.) in the Treatment of Tinea Pedis Completed NCT03824912 Phase 3 Ketoconazole Cream 2%;Ketoconazole Cream 2% (G&W Laboratories Inc.);Placebo
33 A Multi-Center, Randomized, Double-Blind, Vehicle Controlled, Parallel Group Comparison of Econazole Nitrate Foam 1% vs Foam Vehicle and an Evaluator-Blinded Comparison of Econazole Nitrate Foam 1% and Econazole Nitrate Cream 1% in Subjects With Interdigital Tinea Pedis Completed NCT01358240 Phase 3 Econazole Nitrate Foam 1%;Vehicle Foam;Econazole Nitrate Cream 1%
34 A Phase 3 Double-Blind, Randomized, Placebo-Controlled,Multicenter, Parallel Group Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis Completed NCT01290341 Phase 3 NAFT-600 (naftin 2 % gel);Placebo
35 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443898 Phase 3 terbinafine;Placebo;terbinafine;Placebo
36 A Randomized, Double-blind, Vehicle-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Topical Terbinafine Hydrogen Chloride (HCl) Formulation for 24 or 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00443820 Phase 3 terbinafine;Placebo;terbinafine;Placebo
37 A Randomized, Open-label, Active-controlled, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Topical 10% Terbinafine Hydrogen Chloride (HCl) Formulation Versus 5% Amorolfine Nail Lacquer for 48 Weeks of Treatment in Patients With Mild to Moderate Toenail Onychomycosis Completed NCT00459537 Phase 3 terbinafine hydrogen chloride;amorolfine nail lacquer
38 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01270971 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
39 A Randomized, Double-Blind, Vehicle-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of AN2690 Topical Solution, 5%, vs. Solution Vehicle in the Treatment of Onychomycosis of the Toenail in Adults Completed NCT01302119 Phase 3 AN2690 Topical Solution, 5%;Solution Vehicle
40 Design and Clinical Evaluation of a School Meal With Deworming Properties Completed NCT02725255 Phase 2, Phase 3 Albendazole
41 Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. Recruiting NCT02582177 Phase 3 Candicort®;Nizoral®;Baycuten N®;Canesten®
42 A Randomized,Double-blind,Vehicle-controlled, Parallel-design,Multiple-site Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% (Douglas Pharmaceuticals America Ltd) to Ketoconazole Cream 2% (Teva Pharmaceuticals USA Inc.) in the Treatment of Tinea Pedis. Recruiting NCT04203342 Phase 3 Ketoconazole 2% Cream
43 Phase 3, Multicenter, Double-blind, Randomized, Non-inferiority Clinical Trial of Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral®, Janssen-Cilag Farmacêutica Ltda.) in Patients With Tinea Pedis Recruiting NCT03320486 Phase 3 Dapaconazole;Ketoconazole
44 A Double-Blind, Randomized, Parallel Group Comparison of Nizoral Cream (F012), Ketoconazole 2% Cream (F126) and Placebo (F000) in the Treatment of Interdigital Tinea Pedis Terminated NCT01110330 Phase 3 Placebo cream;Ketoconazole 2% cream (formulation F012) (Nizoral);Ketoconazole 2% cream (formulation F126)
45 Non-inferiority, Phase III Clinical Trial Comparing Dapaconazole Cream 2% (Biolab Sanus Farmacêutica Ltda.) Versus Ketoconazole Cream 2% (Nizoral® Janssen-Cilag) in Patients With Tinea Pedis Withdrawn NCT02606383 Phase 3 Dapaconazole;Ketoconazole
46 The Efficacy of CELEXT07 in the Treatment of Toenail Onychomycosis: a Phase 2, Randomized, Double-blind Study Unknown status NCT02644551 Phase 2 CELEXT07;Penlac
47 Evaluation of Preclinical Toxicity of a Siddha Formulation Kandhaga Rasayanam ( KR ) and Its Therapeutic Efficacy in Padarthamarai ( Dermatophytoses ) by an Open Clinical Trial Completed NCT02238912 Phase 2 kandhaga rasayanam
48 A Dose Response Trial to Evaluate Clinical and Mycological Effect of Nitric Oxide in Subjects With Tinea Pedis Completed NCT00893880 Phase 2 1% gaseous Nitric Oxide blended in Oxygen
49 Phase IIa, Two-center, Randomized, Double Blind Study With Parallel Groups to Evaluate the Anti-mycotic and Anti-inflammatory Efficacy of Topical Combinational Product LAS 41003 Versus Corresponding Mono-substances in Patients With Inflammatory Tinea Pedis Completed NCT01096472 Phase 2 LAS41003;LAS189961;LAS189962
50 A Blinded Placebo Controlled Single Cross-over Clinical Trial to Evaluate Fungicidal Activity With Topical Application of 1% Gaseous Nitric Oxide in Subjects With Moderate to Severe Tinea Pedis (Athlete's Foot) Completed NCT00771342 Phase 2 Nitric Oxide;Nitrogen

Search NIH Clinical Center for Dermatophytosis

Genetic Tests for Dermatophytosis

Anatomical Context for Dermatophytosis

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatophytosis:

19
Scalp, Glabrous Skin, Nail

MalaCards organs/tissues related to Dermatophytosis:

40
Skin, Testes, T Cells, Bone, Thyroid, Pituitary, Brain

Publications for Dermatophytosis

Articles related to Dermatophytosis:

(show top 50) (show all 6188)
# Title Authors PMID Year
1
Internal Transcribed Spacer rDNA and TEF-1α Gene Sequencing of Pathogenic Dermatophyte Species and Differentiation of Closely Related Species Using PCR-RFLP of The Topoisomerase II. 61
31606971 2020
2
Mystifying brown, pear-shaped multiseptate structures in the potassium hydroxide mounts of patients with suspected dermatophytosis. 61
31721170 2020
3
Dermatoscopy of tinea corporis. 61
32034804 2020
4
Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice. 61
31724251 2020
5
S1 guidelines: Tinea capitis. 61
32026639 2020
6
Trichoscopy of Tinea Capitis: A Systematic Review. 61
31907867 2020
7
Antifungal combination therapy in dermatophytosis: a clinical insight. 61
31594420 2020
8
The interplay among Th17 and T regulatory cells in the immune dysregulation of chronic dermatophytic infection. 61
31830582 2020
9
Tryptanthrin promotes keratinocyte and fibroblast responses in vitro after infection with Trichophyton benhamiae DSM6916. 61
32024909 2020
10
Minimal inhibitory concentration and upper limit of wild type distribution for 13 antifungal agents against Trichophyton mentagrophytes/interdigitale complex of Indian origin. 61
32015042 2020
11
Antidermatophytic lead compounds from Streptomycetes albidoflavus STV1572a against Tinea infections by Tricophyton mentagrophytes. 61
32027973 2020
12
Image Gallery: Widespread erosive tinea corporis mimicking autoimmune bullous dermatoses in a patient with lung cancer. 61
31598958 2020
13
Novel CARD9 mutation in a patient with chronic invasive dermatophyte infection (tinea profunda). 61
31469433 2020
14
Skin Infections and Outpatient Burn Management: Fungal and Viral Skin Infections. 61
31995350 2020
15
Case of tinea corporis due to terbinafine-resistant Trichophyton interdigitale. 61
31994232 2020
16
Prevalence and clinical characteristics of itch in epidemic-like scenario of dermatophytoses in India: a cross-sectional study. 61
31419346 2020
17
A comment on "First report of tinea corporis caused by Arthroderma benhamiae in Brazil". 61
31898250 2020
18
Tinea Corporis Bullosa Secondary to Trichophyton Verrucosum: A Newer Etiological Agent with Literature Review. 61
32029951 2020
19
Tinea Capitis: An Updated Review. 61
31906842 2020
20
Retrospective two-centre study on prepubertal children with Tinea capitis in Korea. 61
31596519 2020
21
Echoes from the past- changing associations between brain tumors and ethnicity. 61
31756667 2020
22
Modeling dermatophytosis: Guinea pig skin explants represent a highly suitable model to study Trichophyton benhamiae infections. 61
31782188 2020
23
Adult black dot tinea capitis caused by Trichophyton tonsurans complicated with herpes zoster. 61
31923110 2020
24
Efficacies and merits of the Cotton Swab technique to diagnose Tinea Capitis in the Pediatric Population. 61
31940462 2020
25
Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort. 61
31674803 2020
26
Tinea capitis: A single-institution retrospective review from 2010 to 2015. 61
31957924 2020
27
Recent advances in the diagnosis of dermatophytosis. 61
32003043 2020
28
Clinical isolates of Trichophyton rubrum are completely inhibited by photochemical treatment with a γ-cyclodextrin formulation of curcuminoids. 61
31975440 2020
29
Mo-CBP4, a purified chitin-binding protein from Moringa oleifera seeds, is a potent antidermatophytic protein: In vitro mechanisms of action, in vivo effect against infection, and clinical application as a hydrogel for skin infection. 61
32004601 2020
30
Rapid detection of terbinafine resistance in Trichophyton species by Amplified refractory mutation system-polymerase chain reaction. 61
31992797 2020
31
Essential oils of Taxandria fragrans and Melaleuca alternifolia have effective antidermatophytic activities in vitro and in vivo that are antagonised by ketoconazole and potentiated in gold nanospheres. 61
31894699 2020
32
Clinico-mycological study of onychomycosis in a tertiary care hospital-A cross-sectional study. 61
31642133 2020
33
Molecular identification of isolates of the Trichophyton mentagrophytes complex. 61
31929737 2020
34
Dermatologic Problems Commonly Seen by the Allergist/Immunologist. 61
31351991 2020
35
Malassezia (Pityrosporum) Folliculitis Incognito: Malessezia-associated Folliculitis Masked by Topical Corticosteroid Therapy. 61
32038889 2020
36
Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. 61
31648940 2020
37
A new mutation in the SQLE gene of Trichophyton mentagrophytes associated to terbinafine resistance in a couple with disseminated tinea corporis. 61
31611164 2019
38
Tinea corporis caused by Trichophyton equinum transmitted from asymptomatic dogs to two siblings. 61
31820297 2019
39
A unique multidrug-resistant clonal Trichophyton population distinct from Trichophyton mentagrophytes/Trichophyton interdigitale complex causing an ongoing alarming dermatophytosis outbreak in India: Genomic insights and resistance profile. 61
31491507 2019
40
Characterization of Skin Microbiome in Tinea Pedis. 61
31762504 2019
41
Adult black dot tinea capitis caused by Trichophyton tonsurans complicated with herpes zoster. 61
31855965 2019
42
8-Hydroxyquinoline-5-sulfonamides are promising antifungal candidates for the topical treatment of dermatomycosis. 61
31816165 2019
43
Topical ketoconazole: a systematic review of current dermatological applications and future developments. 61
30668185 2019
44
A review of the traditional use of southern African medicinal plants for the treatment of fungal skin infections. 61
31899200 2019
45
In search of the source of dermatophytosis: Epidemiological analysis of Trichophyton verrucosum infection in llamas and the breeder (case report). 61
31538413 2019
46
Tinea unguium caused by terbinafine-resistant Trichophyton rubrum successfully treated with fosravuconazole. 61
31353607 2019
47
Deep dermatophytosis caused by Trichophyton rubrum. 61
31782403 2019
48
Towards a rapid identification and a novel proteomic analysis for dermatophytes from human and animal dermatophytosis. 61
31493312 2019
49
Polarized and ultraviolet dermoscopy for the diagnosis of dermatophytosis of vellus hair. 61
31898639 2019
50
Production of anti-Trichophyton rubrum egg yolk immunoglobulin and its therapeutic potential for treating dermatophytosis. 61
31513894 2019

Variations for Dermatophytosis

Expression for Dermatophytosis

Search GEO for disease gene expression data for Dermatophytosis.

Pathways for Dermatophytosis

GO Terms for Dermatophytosis

Biological processes related to Dermatophytosis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.85 IL17A DEFB4A CLEC4E CD4 CCR6
2 defense response to bacterium GO:0042742 9.78 LTF DEFB4A CLEC4E CLEC4D
3 defense response to Gram-negative bacterium GO:0050829 9.67 LTF DEFB4A CD4
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.56 CLEC6A CLEC4E CLEC4D CARD9
5 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.55 LTF FLNA CLEC6A CD4 CARD9
6 cell junction assembly GO:0034329 9.52 FLNC FLNA
7 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.51 CLEC7A CD4
8 innate immune response GO:0045087 9.5 TRIM4 CSF1 CLEC7A CLEC6A CLEC4E CLEC4D
9 pattern recognition receptor signaling pathway GO:0002221 9.43 CLEC7A CLEC4E
10 positive regulation of monocyte differentiation GO:0045657 9.4 CSF1 CD4
11 Fc-gamma receptor signaling pathway GO:0038094 9.37 CLEC4E CLEC4D
12 T cell differentiation involved in immune response GO:0002292 9.32 CLEC4E CLEC4D
13 immune system process GO:0002376 9.23 LTF CSF1 CLEC7A CLEC6A CLEC4E CLEC4D

Molecular functions related to Dermatophytosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 carbohydrate binding GO:0030246 8.92 CLEC7A CLEC6A CLEC4E CLEC4D

Sources for Dermatophytosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....